Embodiments are described herein that relate to transcatheter prosthetic heart valves and/or the inner flow control components thereof, and methods for the delivery and/or deployment of such prosthetic heart valves and/or inner flow control components.
Prosthetic heart valves can pose challenges for delivery and deployment within a heart, particularly for delivery by catheters through the patient's vasculature rather than through a surgical approach. Delivery of traditional transcatheter prosthetic valves generally includes compressing the valve in a radial direction and loading the valve into a delivery catheter such that a central annular axis of the valve is parallel to a lengthwise axis of the delivery catheter. The valves are deployed from the end of the delivery catheter and expanded outwardly in a radial direction from the central annular axis. The expanded size (e.g., diameter) of traditional valves, however, can be limited by the internal diameter of the delivery catheter. The competing interest of minimizing delivery catheter size presents challenges to increasing the expanded diameter of traditional valves (e.g., trying to compress too much material and structure into too little space).
Some transcatheter prosthetic valves can be configured for side and/or orthogonal delivery, which can have an increased expanded diameter relative to traditional valves. For example, in a side and/or an orthogonal delivery, the valve and/or valve frame is compressed and loaded into a delivery catheter such that a central annular axis of the valve and/or valve frame is substantially orthogonal to the lengthwise axis of the delivery catheter, which can allow the valve to be compressed laterally and extended longitudinally (e.g., in a direction parallel to the lengthwise axis of the delivery catheter). In such implementations, it is desirable to provide an inner flow control component that is compatible with the lateral compression and/or longitudinal extension experienced during delivery. Moreover, in some implementations, it is desirable to provide a prosthetic valve with an outer portion or frame that has a size and/or shape that corresponds to a size and/or shape of the annulus of the native valve while providing an inner flow control component that has a substantially cylindrical shape that allows for optimal function of the prosthetic valve leaflets included therein.
Accordingly, a need exists for prosthetic heart valves and/or the inner flow control components thereof, and methods for the delivery and/or deployment of such prosthetic heart valves and/or inner flow control components.
The embodiments described herein relate generally to transcatheter prosthetic heart valves and/or the inner flow control components thereof, and methods for delivering and/or deploying the same. In some embodiments, a side-deliverable prosthetic heart valve includes an outer frame and a flow control component. The outer frame defines a central channel that extends along a central axis of the outer frame. The flow control component is disposed within the central channel and coupled to the outer frame. The flow control component has an inner frame and a set of leaflets coupled to the inner frame. The prosthetic valve is configured to be folded along a longitudinal axis and compressed along the central axis to place the prosthetic valve in a compressed configuration for delivery via a delivery catheter. The longitudinal axis is substantially parallel to a lengthwise axis of the delivery catheter when the prosthetic valve is disposed therein. The prosthetic valve is configured to transition to an expanded configuration when the prosthetic valve is released from the delivery catheter. The flow control component elastically deforms from a substantially cylindrical configuration to a substantially flattened configuration when the prosthetic valve is placed in the compressed configuration.
Disclosed embodiments are directed to transcatheter prosthetic heart valves and/or components thereof, and methods of manufacturing, loading, delivering, and/or deploying the transcatheter prosthetic valves and/or components thereof. In some embodiments, a side-deliverable prosthetic heart valve includes an outer frame and a flow control component. The outer frame defines a central channel that extends along a central axis of the outer frame. The flow control component is disposed within the central channel and coupled to the outer frame. The flow control component has an inner frame and a set of leaflets coupled to the inner frame. The prosthetic valve is configured to be folded along a longitudinal axis and compressed along the central axis to place the prosthetic valve in a compressed configuration for delivery via a delivery catheter. The longitudinal axis is substantially parallel to a lengthwise axis of the delivery catheter when the prosthetic valve is disposed therein. The prosthetic valve is configured to transition to an expanded configuration when the prosthetic valve is released from the delivery catheter. The flow control component elastically deforms from a substantially cylindrical configuration to a substantially flattened configuration when the prosthetic valve is placed in the compressed configuration.
In some embodiments, a side-deliverable prosthetic heart valve includes an outer frame and a flow control component. The outer frame defines a central channel that extends along a central axis of the outer frame. The flow control component has an inner frame and a set of leaflets coupled to the inner frame. The flow control component is configured to be disposed within the central channel and coupled to the outer frame such that an axis defined by the inner frame of the flow control component is offset from the central axis of the outer frame.
In some embodiments, a method for compressing a side-deliverable prosthetic heart valve for transcatheter delivery to a desired location in the body includes folding the side-deliverable prosthetic heart valve along a longitudinal axis. The side-deliverable prosthetic heart valve has an outer frame that defines a central channel and a flow control component disposed within the central channel and coupled to the outer frame. The flow control component has an inner frame and a plurality of leaflets coupled to the inner frame. The flow control component is configured to elastically deform from a first configuration in which a perimeter of the inner frame is substantially cylindrical to a second configuration in which a perimeter of the inner frame is substantially flattened in response to the folding. The side-deliverable prosthetic heart valve is compressed along a central axis of the outer frame to place the side-deliverable prosthetic heart valve in a compressed configuration. The central axis is orthogonal to the longitudinal axis and the central channel extends in the direction of the central axis. The side-deliverable prosthetic heart valve is inserted into a lumen of a delivery catheter such that the longitudinal axis of the side-deliverable prosthetic heart valve is substantially parallel to a lengthwise axis of the delivery catheter.
General Description
As described in detail herein, prosthetic heart valves can have a valve frame and a flow control component mounted within a central lumen or aperture of the valve frame. The flow control component can be configured to permit blood flow in a first direction through an inflow end of the valve and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve. The valves can be compressible and expandable along a long-axis (e.g., a longitudinal axis) substantially parallel to a lengthwise cylindrical axis of a delivery catheter used to deliver the valves. The valves can be configured to transition between a compressed configuration for introduction into the body using the delivery catheter, and an expanded configuration for implanting at a desired location in the body.
Any of the prosthetic heart valves described herein can be a relatively low profile, side-deliverable implantable prosthetic heart valve. Any of the prosthetic heart valves can be transcatheter prosthetic heart valves configured to be delivered into a heart via a delivery catheter. The prosthetic heart valves can have at least an annular outer valve frame and an inner flow control component (e.g., a 2-leaflet or 3-leaflet valve, sleeve, and/or the like) mounted in the valve frame. In some embodiments, the prosthetic heart valves can be a single or a dual-tab prosthetic heart valve. For example, a prosthetic heart valve can include an outer frame that includes or is coupled to a distal anchoring element (e.g., a sub-annular distal anchoring tab or the like) configured to extend into a right or a left ventricular outflow tract (RVOT or LVOT, respectively). In some implementations, a prosthetic heart valve can include a distal anchoring element and a proximal anchoring element (e.g., a sub-annular proximal anchoring tab) configured to extend into the proximal sub-annular space, preferably between the anterior and the posterior leaflets of the heart.
Any of the prosthetic heart valves described herein can be configured to transition between an expanded configuration and a compressed configuration. For example, any of the embodiments described herein can be a balloon-inflated prosthetic heart valve, a self-expanding prosthetic heart valve, and/or the like.
Any of the prosthetic heart valves described herein can be compressible—into the compressed configuration—in a lengthwise or orthogonal direction relative to the central axis of the flow control component that can allow a large diameter valve (e.g., having a height of about 5-60 mm and a diameter of about 20-80 mm) to be delivered and deployed from the inferior vena cava directly into the annulus of a native mitral or tricuspid valve using, for example, a 24-36 Fr delivery catheter and without delivery and deployment from the delivery catheter at an acute angle of approach.
Any of the prosthetic heart valves described herein can have a central axis that is co-axial or at least substantially parallel with blood flow direction through the valve. In some embodiments, the compressed configuration of the valve is orthogonal to the blood flow direction. In some embodiments, the compressed configuration of the valve is parallel to or aligned with the blood flow direction. In some embodiment, the valve can be compressed to the compressed configuration in two directions—orthogonal to the blood flow direction (e.g., laterally) and parallel to the blood flow (e.g., axially). In some embodiments, a long-axis or longitudinal axis is oriented at an intersecting angle of between 45-135 degrees to the first direction when in the compressed configuration and/or the expanded configuration.
Any of the prosthetic heart valves described herein can include an anchoring element extending from a distal side of a valve frame, which can be used, for example, as a Right Ventricular Outflow Tract (“RVOT”) tab or a Left Ventricular Outflow Tract (“LVOT”) tab. Any of the valves described herein can also include an anchoring element extending from a proximal sided of the valve frame, which can be used, for example, to anchor the valve to a proximal sub-annular space. The anchoring elements can include and/or can be formed from a wire loop or wire frame, an integrated frame section, and/or a stent, extending from about 10-40 mm away from the tubular frame.
Any of the prosthetic heart valves described herein can include (i) an upper anchoring element attached to a distal upper edge of the tubular frame, the upper anchoring element can include or be formed from a wire loop or wire frame extending from about 2-20 mm away from the tubular frame, and (ii) a lower anchoring element (e.g., used as a RVOT tab) extending from a distal side of the tubular frame, the lower anchoring element can include and/or can be formed from a wire loop or wire frame extending from about 10-40 mm away from the tubular frame.
Any of the prosthetic heart valves described herein can include a distal lower anchoring element configured to be positioned into the RVOT of the right ventricle and a proximal lower anchoring element configured to be positioned into a sub-annular position in contact with and/or adjacent to sub-annular tissue of the right ventricle. The transcatheter prosthetic heart valve can also include a distal upper anchoring element configured to be positioned into a supra-annular position in contact with and/or adjacent to supra-annular tissue of the right atrium. The distal upper anchoring element can provide a supra-annular downward force in the direction of the right ventricle and the distal and proximal lower anchoring elements can provide a sub-annular upward force in the direction of the right atrium.
Any of the prosthetic heart valves described herein can include an outer support frame comprised of a set of compressible wire cells having an orientation and cell geometry substantially orthogonal to the central axis to minimize wire cell strain when the outer support frame is in a compressed configuration, a rolled and compressed configuration, or a folded and compressed configuration.
In some embodiments, an outer support frame has a lower body portion and an upper collar portion. The lower body portion forms a shape such as a funnel, cylinder, flat cone, or circular hyperboloid when the outer support frame is in an expanded configuration. In some embodiments, the outer support frame is comprised of a wire, a braided wire, or a laser-cut wire frame, and is covered with a biocompatible material. The biocompatible material can be covered such that an inner surface is covered with pericardial tissue, an outer surface is covered with a woven synthetic polyester material, and/or both the inner surface is covered with pericardial tissue and the outer surface is covered with a woven synthetic polyester material.
In some embodiments, an outer support frame has a side profile of a flat cone shape having an outer diameter R of 40-80 mm, an inner diameter r of 20-60 mm, and a height of 5-60 mm. In some embodiments, an annular support frame has a side profile of an hourglass shape having a top diameter R1 of 40-80 mm, a bottom diameter R2 of 50-70 mm, an internal diameter r of 20-60 mm, and a height of 5-60 mm.
Any of the prosthetic heart valves described herein and/or any component, feature, and/or aspect thereof can be similar to and/or substantially the same as the prosthetic heart valves (or components, features, and/or aspects thereof) described in International Patent Application No. PCT/US2019/051957, entitled “Transcatheter Deliverable Prosthetic Heart Valves and Method of Delivery,” filed Sep. 19, 2019 (referred to herein as “the '957 PCT”) and/or International Patent Application No. PCT/US2019/067010, entitled “Transcatheter Deliverable Prosthetic Heart Valves and Methods of Delivery,” filed Dec. 18, 2019 (referred to herein as “the '010 PCT”), the disclosures of which are incorporated herein by reference in their entireties.
Any of the prosthetic heart valves described herein can include an inner flow control component that has a leaflet frame with 2-4 flexible leaflets mounted thereon. The 2-4 leaflets are configured to permit blood flow in a first direction through an inflow end of the flow control component and block blood flow in a second direction, opposite the first direction, through an outflow end of the flow control component. The leaflet frame can include two or more panels of diamond-shaped or eye-shaped wire cells made from heat-set shape memory alloy material such as, for example, Nitinol. The leaflet frame can be configured to be foldable along a z-axis (e.g., a longitudinal axis) from a rounded or cylindrical configuration to aflattened cylinder configuration, and compressible along a vertical y-axis (e.g., a central axis) to a compressed configuration. In some implementations, the leaflet frame can include a pair of hinge areas, fold areas, connection points, etc. that can allow the leaflet frame to be folded flat along the z-axis prior to the leaflet frame being compressed along the vertical y-axis. The inner frame can be, for example, a single-piece structure with two or more living hinges (e.g., stress concentration riser and/or any suitable structure configured to allow for elastic/nonpermanent deformation of the inner frame). In other implementations, the inner frame can be a two-piece structure where the hinge areas are formed using a secondary attachment method (e.g. sutures, fabrics, molded polymer components, etc.)
In some embodiments, the inner flow control component in an expanded configuration forms a shape such as a funnel, cylinder, flat cone, or circular hyperboloid. In some embodiments, the inner flow control component has a leaflet frame comprised of a wire, a braided wire, or a laser-cut wire. In some embodiments, a leaflet frame can have a side profile of a flat cone shape having an outer diameter R of 20-60 mm, an inner diameter r of 10-50 mm, where diameter R is great than diameter r, and a height of 5-60 mm.
Any method for manufacturing prosthetic heart valves described herein can include using additive or subtractive metal or metal-alloy manufacturing to produce a self-expanding outer support frame having a central channel and an outer perimeter wall circumscribing a central vertical axis. A collapsible flow control component is mounted within the outer support frame and configured to permit blood flow in a first direction through an inflow end of the valve and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve. The flow control component has a leaflet frame with 2-4 flexible leaflets mounted. The leaflet frame can be formed using additive or subtractive metal or metal-allow manufacturing. The additive metal or metal-alloy manufacturing can be 3D printing, direct metal laser sintering (powder melt), and/or the like. The subtractive metal or metal-alloy manufacturing is photolithography, laser sintering/cutting, CNC machining, electrical discharge machining, and/or the like. In some embodiments, a process of manufacturing can further include mounting the flow control component within the outer support frame, and covering an outer surface of the outer support frame with a pericardium material or similar biocompatible material.
Any method for delivering prosthetic heart valves described herein can include orthogonal delivery of the prosthetic heart valve to a desired location in the body that includes (i) advancing a delivery catheter to the desired location in the body and (ii) delivering the prosthetic heart valve to the desired location in the body by releasing the valve from the delivery catheter. The valve is in a compressed configuration when in the delivery catheter and transitions to an expanded configuration when released from the delivery catheter.
Any method for delivering prosthetic heart valves described herein can include at least one of (i) compressing the valve along a central vertical axis to reduce a vertical dimension of the valve from top to bottom to place the valve in a compressed configuration, (ii) unilaterally rolling the valve into a compressed configuration from one side of the annular support frame, (iii) bilaterally rolling the valve into a compressed configuration from two opposing sides of the annular support frame, (iv) flattening the valve into two parallel panels that are substantially parallel to the long-axis, (v) flattening the valve into two parallel panels that are substantially parallel to the long-axis and then rolling the flattened valve into a compressed configuration, or (vi) flattening the valve into two parallel panels that are substantially parallel to the long-axis and then compressing the valve along a central vertical axis to reduce a vertical dimension of the valve from top to bottom to place the valve in a compressed configuration.
Any method for delivering prosthetic heart valves described herein can include attaching a pulling wire (e.g., a rigid elongated pulling/pushing rod or draw wire) to a sidewall or an anchoring element (e.g., a distal anchoring element) of the prosthetic heart valve and pulling the valve into and/or through a delivery catheter.
Any method for delivering prosthetic heart valves described herein can include releasing the valve from the delivery catheter by (i) pulling the valve out of the delivery catheter using a pulling wire or rod that is releasably connected to a sidewall or an anchoring element, wherein advancing the pulling wire away from the delivery catheter pulls the compressed valve out of the delivery catheter, or (ii) pushing the valve out of the delivery catheter using a pushing wire or rod that is releasably connected to a sidewall or an anchoring element, wherein advancing the pushing wire or rod out of from the delivery catheter pushes the compressed valve out of the delivery catheter.
Any method for delivering prosthetic heart valves described herein can include releasing the valve from a delivery catheter while increasing blood flow during deployment of the valve by (i) partially releasing the valve from the delivery catheter to establish blood flow around the partially released valve and blood flow through the flow control component; (ii) completely releasing the valve from the delivery catheter while maintaining attachment to the valve to transition to a state with increased blood flow through the flow control component and decreased blood flow around the valve; (iii) deploying the valve into a final mounted position in a native annulus to transition to a state with complete blood flow through the flow control component and minimal or no blood flow around the valve; and (iv) disconnecting and withdrawing a positioning catheter, pulling or pushing wire or rod, and/or the delivery catheter.
Any method for delivering prosthetic heart valves described herein can include orthogonal delivery of the prosthetic heart valve to a native annulus of a human heart that includes at least one of (i) advancing the delivery catheter to the tricuspid valve or pulmonary artery of the heart through the inferior vena cava (IVC) via the femoral vein, (ii) advancing to the tricuspid valve or pulmonary artery of the heart through the superior vena cava (SVC) via the jugular vein, or (iii) advancing to the mitral valve of the heart through a trans-atrial approach (e.g., fossa ovalis or lower), via the IVC-femoral or the SVC jugular approach; and (iv) delivering the prosthetic heart valve to the native annulus by releasing the valve from the delivery catheter.
Any method for delivering prosthetic heart valves described herein can positioning the distal anchoring tab of the heart valve prosthesis into a ventricular outflow tract of the left or right ventricle. In some embodiments, the method can further include positioning an upper distal anchoring tab into a supra-annular position, where the upper distal anchoring tab provides a supra-annular downward force in the direction of the ventricle and the distal anchoring tab (e.g., the lower distal anchoring tab) provides a sub-annular upward force in the direction of the atrium. In some embodiments, the method can further include anchoring one or more tissue anchors attached to the valve into native tissue.
Any method for delivering prosthetic heart valves described herein and/or any portion thereof can be similar to and/or substantially the same as one or more methods for delivering prosthetic heart valves (or portion(s) thereof) described in the '957 PCT and/or the '010 PCT.
The terminology used herein is for the purpose of describing particular embodiments only and is not intended to limit the full scope of the claims. As used herein, the singular forms “a”, “an” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise. With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity.
In general, terms used herein, and especially in the appended claims (e.g., bodies of the appended claims) are generally intended as “open” terms (e.g., the term “including” should be interpreted as “including but not limited to,” the term “having” should be interpreted as “having at least,” etc.). Similarly, the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers (or fractions thereof), steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers (or fractions thereof), steps, operations, elements, components, and/or groups thereof. As used in this document, the term “comprising” means “including, but not limited to.”
As used herein the term “and/or” includes any and all combinations of one or more of the associated listed items. It should be understood that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
All ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof unless expressly stated otherwise. Any listed range should be recognized as sufficiently describing and enabling the same range being broken down into at least equal subparts unless expressly stated otherwise. As will be understood by one skilled in the art, a range includes each individual member.
Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Nothing in this disclosure is to be construed as an admission that the embodiments described in this disclosure are not entitled to antedate such disclosure by virtue of prior invention.
The term “valve prosthesis,” “prosthetic heart valve,” and/or “prosthetic valve” can refer to a combination of a frame and a leaflet or flow control structure or component, and can encompass both complete replacement of an anatomical part (e.g., a new mechanical valve replaces a native valve), as well as medical devices that take the place of and/or assist, repair, or improve existing anatomical parts (e.g., the native valve is left in place).
The disclosed valves include a member (e.g., a frame) that can be seated within a native valve annulus and can be used as a mounting element for a leaflet structure, a flow control component, or a flexible reciprocating sleeve or sleeve-valve. It may or may not include such a leaflet structure or flow control component, depending on the embodiment. Such members can be referred to herein as an “annular support frame,” “tubular frame,” “wire frame,” “valve frame,” “flange,” “collar,” and/or any other similar terms.
The term “flow control component” can refer in a non-limiting sense to a leaflet structure having 2-, 3-, 4-leaflets of flexible biocompatible material such a treated or untreated pericardium that is sewn or joined to an annular support frame, to function as a prosthetic heart valve. Such a valve can be a heart valve, such as a tricuspid, mitral, aortic, or pulmonary, that is open to blood flowing during diastole from atrium to ventricle, and that closes from systolic ventricular pressure applied to the outer surface. Repeated opening and closing in sequence can be described as “reciprocating.” The flow control component is contemplated to include a wide variety of (bio) prosthetic artificial heart valves. Bioprosthetic pericardial valves can include bioprosthetic aortic valves, bioprosthetic mitral valves, bioprosthetic tricuspid valves, and bioprosthetic pulmonary valves.
Any of the disclosed valve embodiments may be delivered by a transcatheter approach. The term “transcatheter” is used to define the process of accessing, controlling, and/or delivering a medical device or instrument within the lumen of a catheter that is deployed into a heart chamber (or other desired location in the body), as well as an item that has been delivered or controlled by such as process. Transcatheter access is known to include cardiac access via the lumen of the femoral artery and/or vein, via the lumen of the brachial artery and/or vein, via lumen of the carotid artery, via the lumen of the jugular vein, via the intercostal (rib) and/or sub-xiphoid space, and/or the like. Moreover, transcatheter cardiac access can be via the inferior vena cava (IVC), superior vena cava (SVC), and/or via a trans-atrial (e.g., fossa ovalis or lower). Transcatheter can be synonymous with transluminal and is functionally related to the term “percutaneous” as it relates to delivery of heart valves. As used herein, the term “lumen” can refer to the inside of a cylinder or tube. The term “bore” can refer to the inner diameter of the lumen.
The mode of cardiac access can be based at least in part on “body channel” may be used to define a blood conduit or vessel within the body, the particular application of the disclosed embodiments of prosthetic valves determines the body channel at issue. An aortic valve replacement, for example, would be implanted in, or adjacent to, the aortic annulus. Likewise, a tricuspid or mitral valve replacement would be implanted at the tricuspid or mitral annulus. Certain features are particularly advantageous for one implantation site or the other. However, unless the combination is structurally impossible, or excluded by claim language, any of the valve embodiments described herein could be implanted in any body channel.
The term “expandable” as used herein may refer to a component of the heart valve capable of expanding from a first, delivery diameter to a second, implantation diameter. An expandable structure, therefore, does not mean one that might undergo slight expansion from a rise in temperature, or other such incidental cause. Conversely, “non-expandable” should not be interpreted to mean completely rigid or a dimensionally stable, as some slight expansion of conventional “non-expandable” heart valves, for example, may be observed.
Any of the disclosed valve embodiments may be delivered via traditional transcatheter delivery techniques or via orthogonal delivery techniques. For example, traditional delivery of prosthetic valves can be such that a central cylinder axis of the valve is substantially parallel to a length-wise axis of the delivery catheter. Typically, the valves are compressed in a radial direction relative to the central cylinder axis and advanced through the lumen of the delivery catheter. The valves are deployed from the end of the delivery catheter and expanded outwardly in a radial direction from the central cylinder axis.
As used herein the terms “side-delivered,” “side-delivery,” “orthogonal delivery,” “orthogonally delivered,” and/or so forth can be used interchangeably to describe such a delivery method and/or a valve delivered using such a method. Orthogonal delivery of prosthetic valves can be such that the central cylinder axis of the valve is substantially orthogonal to the length-wise axis of the delivery catheter. With orthogonal delivery, the valves are compressed (or otherwise reduced in size) in a direction substantially parallel to the central cylinder axis and/or in a lateral direction relative to the central cylinder axis. As such, a length-wise axis (e.g., a longitudinal axis) of an orthogonally delivered valve is substantially parallel to the length-wise axis of the delivery catheter. In other words, an orthogonally delivered prosthetic valve is compressed and/or delivered at a roughly 90 degree angle compared to traditional processes of compressing and delivering transcatheter prosthetic valves. Moreover, prosthetic valves configured to be orthogonally delivered and the processes of delivering such valves are described in detail in the '957 PCT and/or the '010 PCT incorporated by reference hereinabove.
Mathematically, the term “orthogonal” refers to an intersecting angle of 90 degrees between two lines or planes. As used herein, the term “substantially orthogonal” refers to an intersecting angle of 90 degrees plus or minus a suitable tolerance. For example, “substantially orthogonal” can refer to an intersecting angle ranging from 75 to 105 degrees.
Any of the prosthetic valves and/or components thereof may be fabricated from any suitable biocompatible material or combination of materials. For example, an outer valve frame, an inner valve frame (e.g., of an inner flow control component), and/or components thereof may be fabricated from biocompatible metals, metal alloys, polymer coated metals, and/or the like. Suitable biocompatible metals and/or metal alloys can include stainless steel (e.g., 316 L stainless steel), cobalt chromium (Co—Cr) alloys, nickel-titanium alloys (e.g., Nitinol®), and/or the like. Moreover, any of the outer or inner frames described herein can be formed from superelastic or shape-memory alloys such as nickel-titanium alloys (e.g., Nitinol®). Suitable polymer coatings can include polyethylene vinyl acetate (PEVA), poly-butyl methacrylate (PBMA), translute Styrene Isoprene Butadiene (SIBS) copolymer, polylactic acid, polyester, polylactide, D-lactic polylactic acid (DLPLA), polylactic-co-glycolic acid (PLGA), and/or the like. Some such polymer coatings may form a suitable carrier matrix for drugs such as, for example, Sirolimus, Zotarolimus, Biolimus, Novolimus, Tacrolimus, Paclitaxel, Probucol, and/or the like.
Some biocompatible synthetic material(s) can include, for example, polyesters, polyurethanes, polytetrafluoroethylene (PTFE) (e.g., Teflon), and/or the like. Where a thin, durable synthetic material is contemplated (e.g., for a covering), synthetic polymer materials such expanded PTFE or polyester may optionally be used. Other suitable materials may optionally include elastomers, thermoplastics, polyurethanes, thermoplastic polycarbonate urethane, polyether urethane, segmented polyether urethane, silicone polyether urethane, polyetheretherketone (PEEK), silicone-polycarbonate urethane, polypropylene, polyethylene, low-density polyethylene (LDPE), high-density polyethylene (HDPE), ultra-high density polyethylene (UHDPE), polyolefins, polyethylene-glycols, polyethersulphones, polysulphones, polyvinylpyrrolidones, polyvinylchlorides, other fluoropolymers, polyesters, polyethylene-terephthalate (PET) (e.g., Dacron), Poly-L-lactic acids (PLLA), polyglycolic acid (PGA), poly(D, L-lactide/glycolide) copolymer (PDLA), silicone polyesters, polyamides (Nylon), PTFE, elongated PTFE, expanded PTFE, siloxane polymers and/or oligomers, and/or polylactones, and block co-polymers using the same.
Any of the outer valve frames, inner valve frames (e.g., of the flow control components), and/or portions or components thereof can be internally or externally covered, partially or completely, with a biocompatible material such as pericardium. A valve frame may also be optionally externally covered, partially or completely, with a second biocompatible material such as polyester or Dacron®. Disclosed embodiments may use tissue, such as a biological tissue that is a chemically stabilized pericardial tissue of an animal, such as a cow (bovine pericardium), sheep (ovine pericardium), pig (porcine pericardium), or horse (equine pericardium). Preferably, the tissue is bovine pericardial tissue. Examples of suitable tissue include that used in the products Dura-Guard®, Peri-Guard®, and Vascu-Guard®, all products currently used in surgical procedures, and which are marketed as being harvested generally from cattle less than 30 months old.
The embodiments herein and the various features and advantageous details thereof are explained more fully with reference to the non-limiting embodiments that are illustrated in the accompanying drawings and detailed in the following description. Descriptions of well-known components and processing techniques are omitted so as to not unnecessarily obscure the embodiments herein. The examples used herein are intended merely to facilitate an understanding of ways in which the embodiments herein may be practiced and to further enable those of skill in the art to practice the embodiments herein. Accordingly, the examples should not be construed as limiting the scope of the embodiments herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the inventive concepts to those skilled in the art. Like numbers refer to like elements throughout.
The transcatheter prosthetic valve 102 (also referred to herein as “prosthetic valve” or simply “valve”) is compressible and expandable in at least one direction relative to a long-axis 111 of the valve 102 (also referred to herein as “horizontal axis,” “longitudinal axis,” or “lengthwise axis”). The valve 102 is configured to compressible and expandable between an expanded configuration (
In some embodiments, the valve 102 can be centric, or radially symmetrical. In other embodiments, the valve 102 can be eccentric, or radially (y-axis) asymmetrical. In some eccentric embodiments, the valve 102 (or an outer frame thereof) may have a D-shape (viewed from the top) so the flat portion can be matched to the anatomy in which the valve 102 will be deployed. For example, in some instances, the valve 102 may be deployed in the tricuspid annulus and may have a complex shape determined by the anatomical structures where the valve 102 is being mounted. In the tricuspid annulus, the circumference of the tricuspid valve may be a rounded ellipse, the septal wall is known to be substantially vertical, and the tricuspid is known to enlarge in disease states along the anterior-posterior line. In other instances, the valve 102 may be deployed in the mitral annulus (e.g., near the anterior leaflet) and may have a complex shape determined by the anatomical structures where the valve 102 is being mounted. For example, in the mitral annulus, the circumference of the mitral valve may be a rounded ellipse, the septal wall is known to be substantially vertical, and the mitral is known to enlarge in disease states.
In some embodiments, the valve 102 (and/or at least a portion thereof) may start in a roughly tubular configuration, and be heat-shaped to provide an upper atrial cuff or flange for atrial sealing and a lower transannular tubular or cylindrical section having an hourglass cross-section for about 60-80% of the circumference to conform to the native annulus along the posterior and anterior annular segments while remaining substantially vertically flat along 20-40% of the annular circumference to conform to the septal annular segment. While the valve 102 is shown in
As shown, the valve 102 generally includes an annular support frame 110 and a flow control component 150. In addition, the valve 102 and/or at least the annular support frame 110 of the valve 102 optionally can include one or more anchoring element. For example, in the embodiment shown in
The annular support frame 110 (also referred to herein as “tubular frame,” “valve frame,” “wire frame,” “outer frame,” or “fame”) can have or can define an aperture or central channel 114 that extends along a central axis 113. The central channel 114 (e.g., a central axial lumen or channel) can be sized and configured to receive the flow control component 150 across a portion of a diameter of the central channel 114. The frame 110 may have an outer circumferential surface for engaging native annular tissue that may be tensioned against an inner aspect of the native annulus to provide structural patency to a weakened native annular ring.
The frame 110 includes a cuff or collar (not shown) and a tubular, transannular, and/or body section (not shown). The cuff or collar (referred to herein as “collar”) can be attached to and/or can form an upper edge of the frame 110. When the valve 102 is deployed within a human heart, the collar can be an atrial collar. The collar can be shaped to conform to the native deployment location. In a mitral valve replacement, for example, the collar will be configured with varying portions to conform to the native valve and/or a portion of the atrial floor surrounding the mitral valve. In one embodiment, the collar will have a distal and proximal upper collar portion. The distal collar portion can be larger than the proximal upper collar portion to account for annular geometries, supra-annular geometries, and/or subannular geometries. Examples of collars are described below with reference to specific embodiments.
The frame 110 may optionally have a separate atrial collar attached to the upper (atrial) edge of the frame 110, for deploying on the atrial floor that is used to direct blood from the atrium into the flow control component 150 and to seal against blood leakage (perivalvular leakage) around the frame 110. The frame 110 may also optionally have a separate ventricular collar attached to the lower (ventricular) edge of the frame 110, for deploying in the ventricle immediately below the native annulus that is used to prevent regurgitant leakage during systole, to prevent dislodging of the valve 102 during systole, to sandwich or compress the native annulus or adjacent tissue against the atrial cuff or collar, and/or optionally to attach to and support the flow control component 150. Some embodiments may have both an atrial collar and a ventricular collar, whereas other embodiments either include a single atrial collar, a single ventricular collar, or have no additional collar structure.
The frame 110 and/or at least the transannular or body section thereof can be a ring, or cylindrical or conical tube. In some embodiments, the frame 110 and/or at least the transannular or body section thereof may have a side profile of a flat-cone shape, an inverted flat-cone shape (narrower at top, wider at bottom), a concave cylinder (walls bent in), a convex cylinder (walls bulging out), an angular hourglass, a curved, graduated hourglass, a ring or cylinder having a flared top, flared bottom, or both. The frame 110 may have a height in the range of about 5-60 mm, may have an outer diameter dimension, R, in the range of about 20-80 mm, and may have an inner diameter dimension in the range of about 21-79 mm, accounting for the thickness of the frame 110 (e.g., a wire material forming the frame 110).
The frame 110 is compressible for delivery and when released it is configured to return to its original (uncompressed) shape. The frame 110 may be compressed for transcatheter delivery and may be expandable using a transcatheter expansion balloon. In other implementations, the frame 110 can include and/or can be formed of a shape-memory element allowing the frame 110 to be self-expanding. In some instances, suitable shape-memory materials can include metals and/or plastics that are durable and biocompatible. For example, the frame 110 can be made from superelastic metal wire, such as a Nitinol wire or other similarly functioning material. In some embodiments, the frame 110 can be formed from stainless steel, cobalt-chromium, titanium, and/or other functionally equivalent metals and/or alloys.
The frame 110 may be constructed as a wire, a braided wire, or a laser cut wire frame. In some embodiments, the frame 110 can include and/or can form a set of compressible wire cells having an orientation and cell geometry substantially orthogonal to the central vertical axis 113 to minimize wire cell strain when the frame 110 is in a vertical compressed configuration, a rolled and compressed configuration, or a folded and compressed configuration.
The frame 110 may also have and/or form additional functional elements (e.g., loops, anchors, etc.) for attaching accessory components such as biocompatible covers, tissue anchors, releasable deployment and retrieval control guides, knobs, attachments, rigging, and so forth. The frame 110 may be optionally internally or externally covered, partially or completely, with a biocompatible material such as pericardium, polyester, Dacron®, and/or the like. In some implementations, the frame 110 (or aspects and/or portions thereof) can be structurally and/or functionally similar to the frames (or corresponding aspects and/or portions thereof) described in detail in the '957 PCT and/or the '010 PCT.
As described above, the frame 110 and/or the valve 102 can include at least a distal anchoring element 132 and a proximal anchoring element 134. The anchoring elements of the valve 102 and/or the frame 110 can be any suitable shape, size, and/or configuration such as any of those described in detail in the '957 PCT and/or the '010 PCT, and/or any of those described herein with respect to specific embodiments. For example, the distal and proximal anchoring elements 132 and 134 can be, for example, lower anchoring elements (e.g., coupled to and/or included in a lower portion of the frame 110). In some embodiments, the frame 110 and/or the valve 102 can also optionally include one or more of a distal upper anchoring element and a proximal upper anchoring element. The anchoring elements of the frame 110 can include and/or can be formed from a wire loop or wire frame, an integrated frame section, and/or a stent, extending about 10-40 mm away from the frame 110.
The anchoring elements of the valve 102 can be configured to engage a desired portion of the annular tissue to mount the frame 110 to the annulus of the native valve in which the valve 102 is deployed. For example, the distal anchoring element 132 can extend from a lower distal side of the frame 110 and can act, for example, as a Right Ventricular Outflow Tract (“RVOT”) anchor or a Left Ventricular Outflow Tract (“LVOT”) anchor. The proximal anchoring element 134 can be, for example, a proximal lower anchoring element and can be configured to engage subannular tissue of the ventricle to aid in the securement of the valve 102 in the annulus. In some implementations, at least the proximal anchoring element 134 can be configured to transition between a first configuration in which the proximal anchoring element 134 is maintained in a compressed, undeployed, and/or restrained state, to a second configuration in which the proximal anchoring element 134 is expanded, extended, deployed, and/or unrestrained, which can aid in the deployment of the valve 102 in the native annulus, as described in detail in the '010 PCT.
In some embodiments, the frame 110 can include a guidewire collar (not shown) configured to selectively engage and/or receive a portion of a guidewire or a portion of a guidewire assembly and/or can have any suitable configuration. In certain embodiments, the distal lower anchoring element 132 can form and/or can include a feature that forms the guidewire collar. In other implementations, the guidewire collar can be attached to any suitable portion of the frame 110, to the proximal anchoring element 134, and/or to any other anchoring elements and/or features of the frame 110 (e.g., a distal or proximal upper anchoring element). In some embodiments, the guidewire collar is configured to allow a portion of the guidewire to extend through an aperture of the guidewire, thereby allowing the valve 102 to be advanced over or along the guidewire. In some embodiments, the guidewire collar can selectively allow the guidewire to be advanced therethrough while blocking or preventing other elements and/or components such as a pusher or the like.
The flow control component 150 can refer in a non-limiting sense to a device for controlling fluid flow therethrough. In some embodiments, the flow control component 150 can be a leaflet structure having 2-leaflets, 3-leaflets, 4-leaflets, or more, made of flexible biocompatible material such a treated or untreated pericardium. The leaflets can be sewn or joined to a support structure such as an inner frame, which in turn, can be sewn or joined to the outer frame 110.
In some embodiments, the flow control component 150 and/or the inner frame thereof can have a substantially cylindrical or tubular shape when the valve 102 is in the expanded configuration (see e.g.,
In some embodiments, an amount of non-elastic (e.g., permanent) deformation can be maintained below a deformation threshold. For example, in some embodiments, the inner frame can be deformed such that a maximum strain during folding and/or compression is about 6% or less. In some implementations, a deformation threshold can be an amount of difference between major and minor axes of the cylindrical frame post-delivery (e.g., less than about 5% difference). In some implementations, an amount of deflection of one or more portions of the inner frame is less than about 5%. On the other hand, the inner frame can be sufficiently stiff to reduce and/or substantially minimize commissure motion in a vertical direction under pulsatile loads (e.g., associated with the opening and closing of the leaflets). In general, the vertical motion (deflection) at the commissures under hemodynamic pressures (e.g., maximum hemodynamic pressures) can be less than about 5% of the overall valve height. In some implementations, the frame can provide sufficient radial stiffness to limit a radial motion of the commissures. In general, the radial motion (deflection) at the commissures under hemodynamic pressures can be less than about 5% of the diameter of the inner frame.
The inner frame may be constructed as a wire, a braided wire, or a laser cut wire frame. In some embodiments, the inner frame can include and/or can form a set of compressible wire cells having an orientation and cell geometry substantially orthogonal to an axis 151 of the flow control component 150 to minimize wire cell strain when the inner frame is in a compressed configuration. For example, in some embodiments, the inner frame can have any suitable number of elastically deformable diamond-shaped or eye-shaped wire cells, and/or the like. Although not shown in
The flow control component 150 can be mounted within the frame 110 and configured to permit blood flow in a first direction through an inflow end of the valve and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve. For example, the flow control component 150 can be configured such that the valve 102 functions, for example, as a heart valve, such as a tricuspid valve, mitral valve, aortic valve, or pulmonary valve, which can open to blood flowing during diastole from atrium to ventricle, and that can close from systolic ventricular pressure applied to the outer surface. Repeated opening and closing in sequence can be described as “reciprocating.”
As shown in
In some embodiments, the coupling of the flow control component 150 to the frame 110 (e.g., to a drum, collar portion, transannular section, and/or the like) can include coupling the flow control component 150 to a collar of the frame 110 via tissue or a biocompatible mesh or the like; coupling the flow control component 150 to a collar of the frame 110 via tissue or a biocompatible mesh or the like and one or more superelastic or shape-memory alloy structures; coupling the flow control component 150 to a collar of the frame 110 via tissue or a biocompatible mesh or the like and one or more superelastic or shape-memory alloy structures that is integrated into the atrial collar; coupling the flow control component 150 to a collar of the frame 110 via tissue, biocompatible mesh, or the like and one or more woven or knitted fabrics; coupling the flow control component 150 to a collar of the frame 110 via tissue, biocompatible mesh, or the like, which is sutured and/or sewn into place; coupling the flow control component 150 to a collar of the frame 110 via tissue, biocompatible mesh, or the like with a structural and/or fabric cross member that can be folded in the fold direction; and/or any other suitable coupling method.
As described above, the valve 102 is compressible and expandable between the expanded configuration and the compressed configuration. The valve 102 can have a first height or size along the central axis 113 when in the expanded configuration and can have a second height or size, less than the first height or size, along the central axis 113 when in the compressed configuration. The valve 102 can also be compressed in additional directions. For example, the valve 102 can be compressed along the lateral axis 115 that is perpendicular to both the longitudinal axis 111 and the central axis 113.
The valve 102 is compressed during delivery of the valve 102 and is configured to expand once released from the delivery catheter. More specifically, the valve 102 is configured for transcatheter orthogonal delivery to the desired location in the body (e.g., the annulus of a native valve), in which the valve 102 is compressed in an orthogonal or lateral direction relative to the dimensions of the valve 102 in the expanded configuration (e.g., along the central axis 113 and/or the lateral axis 115). During delivery, the longitudinal axis 111 of the valve 102 is substantially parallel to a longitudinal axis of the delivery catheter. In orthogonal delivery, the longitudinal axis 111 is oriented at an intersecting angle between 45 and 135 degrees relative to the central axis 113 (e.g., perpendicular or at about 90 degrees) and is in a substantially parallel orientation relative to a lengthwise cylindrical axis of the delivery catheter.
The valve 102 is in the expanded configuration prior to being loaded into the delivery catheter and/or after being released from the delivery catheter and deployed or implanted (or ready to be deployed or implanted) at the desired location in the body. The shape of the expanded valve 102 can be that of a large diameter shortened cylinder with an extended collar (e.g., the collar). When in the expanded configuration shown in
When in the compressed configuration shown in
Although not shown in
As shown in
The deployment of the valve 102 can include placing the distal anchoring element 132 (e.g., the distal lower anchoring element 132) in the ventricle (RV, LV) below the annulus while the remaining portions of the valve 102 are in the atrium (RA, LA). In some instances, the distal anchoring element 132 can be positioned in an outflow tract of the ventricle (e.g., the distal anchoring element 132 can be advanced over and/or along the guidewire). For example, in some implementations, the valve 102 can be delivered to the annulus of the native tricuspid valve (TV) and at least a portion of the distal anchoring element 132 can be positioned in a right ventricular outflow tract (RVOT). In other implementations, the valve 102 can be delivered to the annulus of the native mitral valve (MV) and at least a portion of the distal anchoring element 132 can be positioned in a left ventricular outflow tract (LVOT). In some instances, the distal anchoring element 134 can engage subannular tissue to at least partially secure the distal end portion of the valve 102 to the native annular tissue while the remainder of the valve 102 is maintained in a supra-annular position within the atrium side of the annulus.
In some implementations, the prosthetic valve 102 can be temporarily maintained in a partially deployed state. For example, the valve 102 can be partially inserted into the annulus and held at an angle relative to the annulus to allow blood to flow from the atrium to the ventricle partially through the native valve annulus around the valve 102, and partially through the valve 102, which can allow for assessment of the valve function.
The valve 102 can be placed or seated in the annulus (PVA, MVA, AVA, and/or TVA) of the native valve (PV, MV, AV, and/or TV) such that the transannular section of the valve frame 110 extends through the annulus and into the ventricle while the collar remains in the atrium in a supra-annular position. For example, in some embodiments, the secondary catheter and/or the pusher (not shown) can be used to push at least the proximal end portion of the valve 102 into the annulus. In some implementations, the proximal anchoring element 134 can be maintained in its first configuration as the valve 102 is seated in the annulus. For example, as described above, the proximal anchoring element 134 can be in contact with, adjacent to, and/or near the transannular section of the frame 110 while in the first configuration, which in turn, can limit an overall circumference of a lower portion of the frame 110, thereby allowing the transannular section of the frame 110 to be inserted through the annulus.
Once seated, the proximal anchoring element 134 can be transitioned from its first configuration to its second configuration, as described in detail in the '010 PCT. Accordingly, once the valve 102 is seated in the annulus, the proximal anchoring element 134 can be placed in its second configuration in which the proximal anchoring element 134 contacts, engages, and/or is otherwise disposed adjacent to subannular tissue. Moreover, in some implementations, the distal anchoring element 132, the proximal anchoring element 134, and the collar (or any other upper anchoring elements) can exert a compressive force on the annular tissue separating the atrium from the ventricle, thereby placing the valve 102 in a fully deployed state. While not shown in
Provided below is a discussion of certain aspects or embodiments of transcatheter prosthetic valves (e.g., prosthetic heart valves). The transcatheter prosthetic valves (or aspects or portions thereof) described below with respect to specific embodiments can be substantially similar in at least form and/or function to the valve 102 and/or corresponding aspects or portions of the valve 102 described above with reference to
The collapsible (inner) flow control component 250 is mounted within the annular outer support frame 210 and is configured to permit blood flow in a first direction, e.g. atrial to ventricular, through an inflow end of the valve 202 and block blood flow in a second direction, opposite the first direction, through an outflow end of the valve 202. The collapsible (inner) flow control component 250 can have a foldable and compressible inner wire frame 252 (also referred to as “inner leaflet frame” or “inner frame”) with a distal fold area 266 and a proximal fold area 261 (e.g., also referred to as a hinge area, coupling area, edge portion or connected edge portion, etc.). A set of 2-4 flexible leaflets 261 are mounted in or on the inner frame 252. In some embodiments, for example, the flow control component 250 has three leaflet 261 cusps or pockets mounted within the inner frame 252 (
As shown in
The inner flow control component 250, like the outer annular frame 210, is foldable and compressible. For example, the leaflet frame 252 is foldable along or in the direction of a z-axis (front to back) from a cylindrical configuration to a flattened cylinder configuration, where the fold lines are located on a distal side and on a proximal side. In some embodiments, being foldable along or in the direction of the z-axis allows the leaflet frame 252 to transition (e.g., flatten) from a ring or cylinder shape to a two-layer band (e.g., folded over on itself), or like a cylinder flattened into a rectangle or square joined along two opposing sides. In some implementations, such an arrangement allows the outer frame 210 and the flow control component 250 to reduce the radius along the z-axis until the side walls are in contact or nearly so. This also allows the outer frame 210 and the flow control component 250 to maintain a desired radius along the horizontal axis (x-axis) to minimize the number of wire cells, which make up the outer and the inner frames, which may be damaged by forces applied during folding and/or compression performed when loading the valve 202 into a delivery catheter.
The flow control component 250 (and thereby the inner leaflet frame 252), like the outer frame 210, is also vertically (y-axis) compressible, reducing the height of the entire valve 202 to fit within an inner diameter of a delivery catheter. By folding (compressing) in the direction of the z-axis and vertically compressing in the y-axis, the valve 202 is permitted to maintain a relatively large dimension along the horizontal, or x-axis. For example, a 60 mm or larger diameter valve can be delivered via transcatheter techniques. In some embodiments, the valve 202 in the expanded configuration has a height of about 5-60 mm or more and a diameter of about 25-80 mm or more. The length of the long axis (e.g., longitudinal axis or x-axis) of a valve, e.g. 60 mm, since it runs parallel to a central axis of the delivery catheter, is not limited by the relatively large amount of wire frame and cover material used for such a large valve. The use of a folded, compressed valve that is orthogonal to the traditional axial-delivery valves permits treatment options not available previously. In some embodiments, the horizontal x-axis of the valve 202 is at an intersecting angle of between 45-135 degrees to the central vertical y-axis when in an expanded configuration. In some embodiments, the horizontal x-axis of the valve 202 in the compressed configuration is substantially parallel to a length-wise cylindrical axis of the delivery catheter.
The annular outer support frame 310 is made from a shape-memory material such as Nickel-Titanium alloy, for example Nitinol, and is therefore a self-expanding structure from a compressed configuration to an expanded configuration. The annular (outer) support frame 310 has a transannular and/or body section 312 that circumscribes, forms, and/or defines a central channel 314 about or along a vertical or central axis (y-axis). The annular support frame 310 has an atrial collar component 320 attached circumferentially at a top edge of the transannular and/or body section 312. The atrial collar 320 is shaped to conform to the native deployment location. In a tricuspid replacement, for example, the atrial collar 320 can have a tall back wall portion to conform to the septal area of the native valve, and can have a distal and proximal upper collar portion. The distal upper collar portion can be larger than the proximal upper collar portion to account for the larger flat space above (atrial) the right ventricular outflow tract (RVOT) sub annular area.
The outer support frame 310 has a distal anchoring element 332 (e.g., a superelastic wire loop distal tab) coupled to and/or extending from a distal side of the outer support frame 310 and a proximal anchoring element 334 (e.g., a superelastic wire loop proximal tab) coupled to and/or extending from a proximal side of the outer support frame 310. In some embodiments, the distal anchoring element 332 and the proximal anchoring element 334 can be integrated tabs that are unitarily constructed with the body section 312 of the outer frame 310. The anchoring elements 332 and 334 may vary in size and shape. For example, a distal anchoring element 332 (e.g., an RVOT tab) may be longer to reach into the entry of the pulmonary artery (in the case of a tricuspid replacement). In some embodiments, the shapes of the anchoring elements 332 and 334 are configured to conform to the A1 and A3 commissural areas of the mitral valve.
At least the outer support frame 310 of the valve 302 is covered, wrapped, and/or surrounded by a biocompatible cover 340. The biocompatible cover 340 can be a mesh material, a pericardial tissue, a woven synthetic polyester material, and/or any other suitable biocompatible material such as those described above.
The collapsible (inner) flow control component 350 is mounted within the annular outer support frame 310 adjacent to the spacer 331. The flow control component 350 has a foldable and compressible inner wire frame 352 (also referred to as “inner leaflet frame” or “inner frame”) with two or more fold areas, hinge areas, coupling areas, elastically deformable regions, etc. A set of 2-4 flexible leaflets 361 are mounted in or on the inner frame 352. In some embodiments, the flow control component 350 has three leaflet 361 cusps or pockets mounted within the inner frame 352 (
The flow control component 350 has a diameter and/or perimeter that is smaller than a diameter and/or perimeter of the central channel 314 of the outer frame 310. Moreover, a central or vertical axis (y-axis) defined by the inner frame 352 is parallel to but offset from the central or vertical axis (y-axis) defined by the outer support frame 310 (
In some embodiments, the spacer element 331 can also provide for controlled regurgitation of the valve 302. For example, in some embodiments, the spacer 331 can be uncovered or covered with a fluid permeable mesh, cloth, and/or biocompatible material. In some embodiments, the uncovered spacer 331 can be later plugged with an inserted stent, cover, plug, and/or the like (e.g., once regurgitation is no longer desirable for the proper functioning of the heart of the patient).
In some embodiments, the spacer element 331 can be similar to or substantially the same as the inner frame 352 of the flow control component 350 without having leaflets mounted therein. In other embodiments, the spacer element 331 can include leaflets mounted therein (e.g., similar in form and/or configuration as the leaflets 361 or different in form and/or configuration from the leaflets 361). Similarly stated, the valve 302 can include two flow control components 350 with each flow control component 350 acting as a spacer with respect to the other flow control component 350.
As described in detail above, the flow control component can include an inner frame that is disposed within a central channel of the outer frame of the valve. In some instances, the inner frame can be offset within the central channel, as described in detail above. The inner frame of the flow control component can be formed of a relatively flexible material such as a superelastic material and/or a shape-memory alloy. In some embodiments, the inner frame can include any suitable number of wire cells (e.g., diamond-shaped cells) that can be arranged and/or oriented to allow the inner frame to elastically deform in response to an applied force. In some embodiments, the inner frame can include lateral fold or hinge areas that can allow the inner frame to elastically deform in response to the folding. For example, the fold or hinge areas can be integrated into the inner frame structure and/or can be a connection point between two portions of the inner frame. For example, the inner frame can include a first member and a second member that are flexibly coupled at the lateral fold or hinge areas. Accordingly, such an arrangement can allow the inner frame to elastically deform in response to the folding.
The side deliverable prosthetic heart valve is compressed along a central axis of the outer frame to place the side deliverable prosthetic heart valve in a compressed configuration, wherein the central axis is orthogonal to the longitudinal axis of the valve, at 12. As described in detail above, the valve can be compressible and/or foldable in all directions lateral to the longitudinal axis. For example, the valve can be compressible along the central axis (e.g., a vertical axis) and foldable along or in the direction of a lateral axis (e.g., an axis orthogonal to both the central axis and the longitudinal axis). Moreover, the inner frame of flow control component can be configured to be compressed elastically when the valve is compressed along the central axis. Thus, the flow control component can elastically deform throughout a process of placing the valve in the compressed configuration.
The side-deliverable prosthetic heart valve is inserted into the lumen of a delivery catheter such that the longitudinal axis of the valve is substantially parallel to a lengthwise axis of the delivery catheter, at 13. As described in detail herein and/or in the '957 PCT and/or the '010 PCT, the valve can be delivered orthogonally and compressed vertically and/or laterally to allow a relatively large prosthetic valve to be delivered to a human heart via a transcatheter approach.
Many modifications and variations can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the disclosure, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the appended claims. The present disclosure is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled. It is to be understood that this disclosure is not limited to particular methods, reagents, compounds, compositions or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Where methods described above indicate certain events occurring in certain order, the ordering of certain events may be modified. Additionally, certain of the events may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above.
Where schematics and/or embodiments described above indicate certain components arranged in certain orientations or positions, the arrangement of components may be modified. While the embodiments have been particularly shown and described, it will be understood that various changes in form and details may be made. Any portion of the apparatus and/or methods described herein may be combined in any combination, except mutually exclusive combinations.
The embodiments described herein can include various combinations and/or sub-combinations of the functions, components, and/or features of the different embodiments described. Various of the above-disclosed and other features and functions, or alternatives thereof, may be combined into many other different systems or applications. Various presently unforeseen or unanticipated alternatives, modifications, variations, or improvements therein may be subsequently made by those skilled in the art, each of which is also intended to be encompassed by the disclosed embodiments.
This application is a continuation of U.S. patent application Ser. No. 17/222,182, entitled “Collapsible Inner Flow Control Component for Side-Deliverable Transcatheter Heart Valve Prosthesis,” filed Apr. 5, 2021, (now U.S. Pat. No. 11,273,032), which is a continuation of International Patent Application No. PCT/US2020/015231, entitled “Collapsible Inner Flow Control Component for Side-Deliverable Transcatheter Heart Valve Prosthesis,” filed on Jan. 27, 2020, which claims priority to and the benefit of U.S. Provisional Patent Application No. 62/797,201, entitled “Collapsible Inner Flow Control Component for Orthogonal Transcatheter Heart Valve Prosthesis,” filed on Jan. 26, 2019. Each of U.S. patent application Ser. No. 17/222,182 and International Patent Application No. PCT/US2020/015231 is also a continuation-in-part of U.S. patent application Ser. No. 16/455,740, entitled “Collapsible Inner Flow Control Component for Side-Delivered Transcatheter Heart Valve Prosthesis,” filed on Jun. 27, 2019 (now U.S. Pat. No. 11,185,409), which claims priority to and the benefit of U.S. Provisional Patent Application No. 62/797,201. The disclosure of each of the foregoing applications is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3744060 | Bellhouse et al. | Jul 1973 | A |
4079468 | Liotta et al. | Mar 1978 | A |
5509428 | Dunlop | Apr 1996 | A |
5554185 | Block et al. | Sep 1996 | A |
5800531 | Cosgrove | Sep 1998 | A |
5906642 | Caudillo et al. | May 1999 | A |
6006134 | Hill et al. | Dec 1999 | A |
6290719 | Garberoglio | Sep 2001 | B1 |
6312464 | Navia | Nov 2001 | B1 |
6449507 | Hill et al. | Sep 2002 | B1 |
6458153 | Bailey et al. | Oct 2002 | B1 |
6532388 | Hill et al. | Mar 2003 | B1 |
6628987 | Hill et al. | Sep 2003 | B1 |
6669724 | Park et al. | Dec 2003 | B2 |
6718208 | Hill et al. | Apr 2004 | B2 |
6769434 | Liddicoat et al. | Aug 2004 | B2 |
6890330 | Streeter et al. | May 2005 | B2 |
6896690 | Lambrecht et al. | May 2005 | B1 |
6904318 | Hill et al. | Jun 2005 | B2 |
6929653 | Strecter | Aug 2005 | B2 |
7175660 | Cartledge et al. | Feb 2007 | B2 |
7201761 | Woolfson et al. | Apr 2007 | B2 |
7225019 | Jahns et al. | May 2007 | B2 |
7269457 | Shafer et al. | Sep 2007 | B2 |
7361189 | Case et al. | Apr 2008 | B2 |
7442204 | Schwammenthal et al. | Oct 2008 | B2 |
7621948 | Herrmann et al. | Nov 2009 | B2 |
7648527 | Agnew | Jan 2010 | B2 |
7749245 | Cohn et al. | Jul 2010 | B2 |
7753949 | Lamphere et al. | Jul 2010 | B2 |
7811316 | Kalmann et al. | Oct 2010 | B2 |
8628571 | Hacohen et al. | Jan 2014 | B1 |
8900295 | Migliazza et al. | Dec 2014 | B2 |
8926694 | Costello | Jan 2015 | B2 |
8986370 | Annest | Mar 2015 | B2 |
8998982 | Richter | Apr 2015 | B2 |
9232995 | Kovalsky et al. | Jan 2016 | B2 |
9308086 | Ho | Apr 2016 | B2 |
9402720 | Richter | Aug 2016 | B2 |
9414915 | Lombardi et al. | Aug 2016 | B2 |
9468525 | Kovalsky | Oct 2016 | B2 |
9504562 | Richter | Nov 2016 | B2 |
9526613 | Gross | Dec 2016 | B2 |
9597181 | Christianson et al. | Mar 2017 | B2 |
9662202 | Quill et al. | May 2017 | B2 |
9788946 | Bobo, Jr. et al. | Oct 2017 | B2 |
9895219 | Costello | Feb 2018 | B2 |
10085834 | Benson | Oct 2018 | B2 |
10321995 | Christianson et al. | Jun 2019 | B1 |
10327895 | Lozonschi et al. | Jun 2019 | B2 |
10463489 | Christianson et al. | Nov 2019 | B2 |
10485662 | Alkhatib | Nov 2019 | B2 |
10485976 | Streeter et al. | Nov 2019 | B2 |
10517718 | Richter | Dec 2019 | B2 |
10537425 | Richter | Jan 2020 | B2 |
10595994 | Christianson et al. | Mar 2020 | B1 |
10631983 | Christianson et al. | Apr 2020 | B1 |
10653522 | Vidlund et al. | May 2020 | B1 |
10653523 | Chambers et al. | May 2020 | B2 |
10758346 | Christianson et al. | Sep 2020 | B1 |
10761511 | Chen et al. | Sep 2020 | B2 |
10779937 | Vidlund et al. | Sep 2020 | B2 |
11071627 | Saikrishnan | Jul 2021 | B2 |
11076956 | Christianson et al. | Aug 2021 | B2 |
11109969 | Vidlund et al. | Sep 2021 | B2 |
11166814 | Vidlund, I et al. | Nov 2021 | B2 |
11173027 | Christianson et al. | Nov 2021 | B2 |
11179239 | Vidlund et al. | Nov 2021 | B2 |
11185409 | Christianson et al. | Nov 2021 | B2 |
11202706 | Christianson et al. | Dec 2021 | B2 |
11234812 | Green | Feb 2022 | B2 |
11234813 | Perrin | Feb 2022 | B2 |
11253359 | Vidlund | Feb 2022 | B2 |
11273032 | Christianson et al. | Mar 2022 | B2 |
11273033 | Christianson et al. | Mar 2022 | B2 |
11278437 | Christianson | Mar 2022 | B2 |
11298227 | Vidlund et al. | Apr 2022 | B2 |
11331186 | Christianson et al. | May 2022 | B2 |
11337807 | Christianson et al. | May 2022 | B2 |
11344412 | Vidlund et al. | May 2022 | B2 |
11344413 | Christianson et al. | May 2022 | B2 |
11712335 | Christianson et al. | Aug 2023 | B2 |
11717399 | Armer | Aug 2023 | B2 |
11786366 | Vidlund et al. | Oct 2023 | B2 |
20020138138 | Yang | Sep 2002 | A1 |
20030040808 | Stack et al. | Feb 2003 | A1 |
20030055495 | Pease | Mar 2003 | A1 |
20040049207 | Goldfarb et al. | Mar 2004 | A1 |
20040088047 | Spence et al. | May 2004 | A1 |
20040093060 | Seguin et al. | May 2004 | A1 |
20040116996 | Freitag | Jun 2004 | A1 |
20040117009 | Cali et al. | Jun 2004 | A1 |
20040167619 | Case et al. | Aug 2004 | A1 |
20040199209 | Hill et al. | Oct 2004 | A1 |
20040225352 | Osborne et al. | Nov 2004 | A1 |
20050010246 | Streeter et al. | Jan 2005 | A1 |
20050075659 | Realyvasquez | Apr 2005 | A1 |
20050075725 | Rowe | Apr 2005 | A1 |
20050107811 | Starksen et al. | May 2005 | A1 |
20050137686 | Salahieh et al. | Jun 2005 | A1 |
20050203614 | Forster | Sep 2005 | A1 |
20050228472 | Case et al. | Oct 2005 | A1 |
20050228495 | Macoviak | Oct 2005 | A1 |
20060173524 | Salahieh et al. | Aug 2006 | A1 |
20060190075 | Jordan et al. | Aug 2006 | A1 |
20060195180 | Kheradvar | Aug 2006 | A1 |
20060195183 | Navia et al. | Aug 2006 | A1 |
20060229708 | Powell et al. | Oct 2006 | A1 |
20060241745 | Solem | Oct 2006 | A1 |
20060276887 | Brady et al. | Dec 2006 | A1 |
20070016286 | Herrmann et al. | Jan 2007 | A1 |
20070073387 | Forster | Mar 2007 | A1 |
20070100427 | Perouse | May 2007 | A1 |
20070239271 | Nguyen | Oct 2007 | A1 |
20080065204 | Macoviak et al. | Mar 2008 | A1 |
20080071287 | Goto | Mar 2008 | A1 |
20080140181 | Reynolds et al. | Jun 2008 | A1 |
20080154355 | Benichou et al. | Jun 2008 | A1 |
20080183279 | Bailey | Jul 2008 | A1 |
20080200980 | Robin et al. | Aug 2008 | A1 |
20080221672 | Lamphere et al. | Sep 2008 | A1 |
20080262592 | Jordan et al. | Oct 2008 | A1 |
20090005863 | Goetz et al. | Jan 2009 | A1 |
20090048656 | Wen | Feb 2009 | A1 |
20090054976 | Tuval et al. | Feb 2009 | A1 |
20090132035 | Roth | May 2009 | A1 |
20090164003 | Kheradvar | Jun 2009 | A1 |
20090192601 | Rafiee et al. | Jul 2009 | A1 |
20100049294 | Zukowski et al. | Feb 2010 | A1 |
20100049313 | Alon et al. | Feb 2010 | A1 |
20100087918 | Vesely | Apr 2010 | A1 |
20100121434 | Paul et al. | May 2010 | A1 |
20100185275 | Richter | Jul 2010 | A1 |
20100280591 | Shin et al. | Nov 2010 | A1 |
20100298929 | Thornton et al. | Nov 2010 | A1 |
20110004237 | Schneider et al. | Jan 2011 | A1 |
20110029072 | Gabbay | Feb 2011 | A1 |
20110066233 | Thornton et al. | Mar 2011 | A1 |
20110071613 | Wood et al. | Mar 2011 | A1 |
20110137397 | Chau et al. | Jun 2011 | A1 |
20110160836 | Behan | Jun 2011 | A1 |
20110172784 | Richter et al. | Jul 2011 | A1 |
20110224785 | Hacohen | Sep 2011 | A1 |
20110245911 | Quill et al. | Oct 2011 | A1 |
20110264191 | Rothstein | Oct 2011 | A1 |
20120022605 | Jahns et al. | Jan 2012 | A1 |
20120022639 | Hacohen et al. | Jan 2012 | A1 |
20120035719 | Forster | Feb 2012 | A1 |
20120065723 | Drasler et al. | Mar 2012 | A1 |
20120083874 | Dale et al. | Apr 2012 | A1 |
20120165928 | Nitzan et al. | Jun 2012 | A1 |
20120203336 | Annest | Aug 2012 | A1 |
20120310327 | McHugo | Dec 2012 | A1 |
20120310328 | Olson et al. | Dec 2012 | A1 |
20130035759 | Gross et al. | Feb 2013 | A1 |
20130046373 | Cartledge | Feb 2013 | A1 |
20130166017 | Cartledge | Jun 2013 | A1 |
20130178931 | Fargahi | Jul 2013 | A1 |
20130190861 | Chau et al. | Jul 2013 | A1 |
20130238089 | Lichtenstein et al. | Sep 2013 | A1 |
20130282110 | Schweich, Jr. et al. | Oct 2013 | A1 |
20130304197 | Buchbinder et al. | Nov 2013 | A1 |
20130304200 | McLean | Nov 2013 | A1 |
20130338764 | Thornton et al. | Dec 2013 | A1 |
20140005778 | Buchbinder et al. | Jan 2014 | A1 |
20140012372 | Chau et al. | Jan 2014 | A1 |
20140018915 | Biadillah et al. | Jan 2014 | A1 |
20140025164 | Montorfano | Jan 2014 | A1 |
20140031924 | Bruchman | Jan 2014 | A1 |
20140039611 | Lane et al. | Feb 2014 | A1 |
20140052237 | Lane et al. | Feb 2014 | A1 |
20140067037 | Fargahi | Mar 2014 | A1 |
20140121763 | Duffy et al. | May 2014 | A1 |
20140135908 | Glozman et al. | May 2014 | A1 |
20140142695 | Gross et al. | May 2014 | A1 |
20140172077 | Bruchman | Jun 2014 | A1 |
20140172083 | Bruchman | Jun 2014 | A1 |
20140194983 | Kovalsky et al. | Jul 2014 | A1 |
20140207231 | Hacohen et al. | Jul 2014 | A1 |
20140222136 | Geist et al. | Aug 2014 | A1 |
20140222142 | Kovalsky et al. | Aug 2014 | A1 |
20140249621 | Eidenschink | Sep 2014 | A1 |
20140257466 | Board et al. | Sep 2014 | A1 |
20140257467 | Lane et al. | Sep 2014 | A1 |
20140277342 | Roeder et al. | Sep 2014 | A1 |
20140277563 | White | Sep 2014 | A1 |
20140288480 | Zimmerman et al. | Sep 2014 | A1 |
20140296962 | Cartledge et al. | Oct 2014 | A1 |
20140296969 | Tegels et al. | Oct 2014 | A1 |
20140296975 | Tegels et al. | Oct 2014 | A1 |
20140350662 | Vaturi | Nov 2014 | A1 |
20140358224 | Tegels et al. | Dec 2014 | A1 |
20140379076 | Vidlund et al. | Dec 2014 | A1 |
20150039081 | Costello | Feb 2015 | A1 |
20150045880 | Hacohen | Feb 2015 | A1 |
20150142103 | Vidlund | May 2015 | A1 |
20150157457 | Hacohen | Jun 2015 | A1 |
20150173897 | Raanani et al. | Jun 2015 | A1 |
20150173898 | Drasler et al. | Jun 2015 | A1 |
20150196390 | Ma et al. | Jul 2015 | A1 |
20150216661 | Hacohen et al. | Aug 2015 | A1 |
20150257878 | Lane et al. | Sep 2015 | A1 |
20150265400 | Eidenschink et al. | Sep 2015 | A1 |
20150282922 | Hingston et al. | Oct 2015 | A1 |
20150282931 | Brunnett et al. | Oct 2015 | A1 |
20150313701 | Krahbichler | Nov 2015 | A1 |
20150335424 | McLean et al. | Nov 2015 | A1 |
20150351906 | Hammer et al. | Dec 2015 | A1 |
20150351910 | Gilmore et al. | Dec 2015 | A1 |
20160008131 | Christianson et al. | Jan 2016 | A1 |
20160038280 | Morriss | Feb 2016 | A1 |
20160081799 | Leo et al. | Mar 2016 | A1 |
20160213470 | Ahlberg et al. | Jul 2016 | A1 |
20160213473 | Hacohen et al. | Jul 2016 | A1 |
20160220363 | Peter | Aug 2016 | A1 |
20160235525 | Rothstein et al. | Aug 2016 | A1 |
20160302921 | Gosal et al. | Oct 2016 | A1 |
20160310274 | Gross et al. | Oct 2016 | A1 |
20160324633 | Gross et al. | Nov 2016 | A1 |
20160324639 | Nguyen | Nov 2016 | A1 |
20160367360 | Cartledge et al. | Dec 2016 | A1 |
20170020670 | Murray et al. | Jan 2017 | A1 |
20170035568 | Lombardi et al. | Feb 2017 | A1 |
20170056163 | Tayeb et al. | Mar 2017 | A1 |
20170056166 | Ratz et al. | Mar 2017 | A1 |
20170071733 | Ghione et al. | Mar 2017 | A1 |
20170071736 | Zhu et al. | Mar 2017 | A1 |
20170100236 | Robertson et al. | Apr 2017 | A1 |
20170128208 | Christianson et al. | May 2017 | A1 |
20170143446 | Kölbel | May 2017 | A1 |
20170172737 | Kuetting et al. | Jun 2017 | A1 |
20170172738 | Kassas | Jun 2017 | A1 |
20170181852 | Kassas | Jun 2017 | A1 |
20170209268 | Cunningham et al. | Jul 2017 | A1 |
20170216023 | Lane et al. | Aug 2017 | A1 |
20170216026 | Quill et al. | Aug 2017 | A1 |
20170245993 | Gross et al. | Aug 2017 | A1 |
20170252163 | Kheradvar | Sep 2017 | A1 |
20170273784 | Racchini et al. | Sep 2017 | A1 |
20170281341 | Lim et al. | Oct 2017 | A1 |
20170319333 | Tegels et al. | Nov 2017 | A1 |
20170325943 | Robin et al. | Nov 2017 | A1 |
20170325948 | Wallace et al. | Nov 2017 | A1 |
20170333240 | Stangenes et al. | Nov 2017 | A1 |
20170348099 | Mendelson et al. | Dec 2017 | A1 |
20170360557 | Kheradvar et al. | Dec 2017 | A1 |
20170360558 | Ma | Dec 2017 | A1 |
20180000586 | Ganesan et al. | Jan 2018 | A1 |
20180014932 | Hammer et al. | Jan 2018 | A1 |
20180021130 | Danino | Jan 2018 | A1 |
20180042721 | Chambers | Feb 2018 | A1 |
20180098847 | Tuseth et al. | Apr 2018 | A1 |
20180116793 | Salahieh et al. | May 2018 | A1 |
20180147055 | Vidlund et al. | May 2018 | A1 |
20180153689 | Maimon et al. | Jun 2018 | A1 |
20180200049 | Chambers et al. | Jul 2018 | A1 |
20180206983 | Noe et al. | Jul 2018 | A1 |
20180256322 | Zhang et al. | Sep 2018 | A1 |
20180256329 | Chambers et al. | Sep 2018 | A1 |
20180263767 | Chau et al. | Sep 2018 | A1 |
20180263773 | Poppe et al. | Sep 2018 | A1 |
20180289474 | Rajagopal et al. | Oct 2018 | A1 |
20180289475 | Chung et al. | Oct 2018 | A1 |
20180296325 | McLean | Oct 2018 | A1 |
20180296341 | Noe et al. | Oct 2018 | A1 |
20180303612 | Pasquino et al. | Oct 2018 | A1 |
20180311037 | Morriss et al. | Nov 2018 | A1 |
20180318071 | Lozonschi et al. | Nov 2018 | A1 |
20180333259 | Dibie | Nov 2018 | A1 |
20180344456 | Barash et al. | Dec 2018 | A1 |
20180353293 | Colavito et al. | Dec 2018 | A1 |
20190000619 | Quijano et al. | Jan 2019 | A1 |
20190008636 | Francis et al. | Jan 2019 | A1 |
20190029819 | Huber | Jan 2019 | A1 |
20190060057 | Cohen et al. | Feb 2019 | A1 |
20190069995 | Levi et al. | Mar 2019 | A1 |
20190105153 | Barash et al. | Apr 2019 | A1 |
20190262129 | Cooper et al. | Aug 2019 | A1 |
20190321171 | Morriss | Oct 2019 | A1 |
20190365538 | Chambers et al. | Dec 2019 | A1 |
20190388219 | Lane et al. | Dec 2019 | A1 |
20200008941 | Stappenbeck et al. | Jan 2020 | A1 |
20200093589 | Christianson et al. | Mar 2020 | A1 |
20200121452 | Saikrishnan et al. | Apr 2020 | A1 |
20200121458 | Vidlund | Apr 2020 | A1 |
20200179146 | Christianson | Jun 2020 | A1 |
20200188097 | Perrin | Jun 2020 | A1 |
20200237506 | Christianson | Jul 2020 | A1 |
20200289259 | Christianson et al. | Sep 2020 | A1 |
20200289263 | Christianson | Sep 2020 | A1 |
20210000592 | Christianson | Jan 2021 | A1 |
20210137677 | Christianson et al. | May 2021 | A1 |
20210154010 | Schneider et al. | May 2021 | A1 |
20210154011 | Christianson | May 2021 | A1 |
20210186693 | Vidlund et al. | Jun 2021 | A1 |
20210220126 | Perrin | Jul 2021 | A1 |
20210220127 | Vidlund et al. | Jul 2021 | A1 |
20210220134 | Christianson et al. | Jul 2021 | A1 |
20210228349 | Vidlund et al. | Jul 2021 | A1 |
20210236280 | Christianson et al. | Aug 2021 | A1 |
20210244533 | Vidlund et al. | Aug 2021 | A1 |
20210244535 | Iyer et al. | Aug 2021 | A1 |
20210244536 | Christianson et al. | Aug 2021 | A1 |
20210290381 | Vidlund et al. | Sep 2021 | A1 |
20210290385 | Christianson et al. | Sep 2021 | A1 |
20210315694 | Vidlund et al. | Oct 2021 | A1 |
20210330459 | Christianson et al. | Oct 2021 | A1 |
20210353412 | Christianson et al. | Nov 2021 | A1 |
20210401572 | Nasr et al. | Dec 2021 | A1 |
20220000614 | Vidlund et al. | Jan 2022 | A1 |
20220087815 | Bernshtein | Mar 2022 | A1 |
20220096226 | Christianson et al. | Mar 2022 | A1 |
20220160504 | Vidlund et al. | May 2022 | A1 |
20220249228 | Vidlund et al. | Aug 2022 | A1 |
20220280292 | Vidlund et al. | Sep 2022 | A1 |
20220280296 | Christianson et al. | Sep 2022 | A1 |
20220296369 | Kheradvar et al. | Sep 2022 | A1 |
20220323212 | Vidlund et al. | Oct 2022 | A1 |
20220338978 | Yushtein | Oct 2022 | A1 |
20220370198 | Nir et al. | Nov 2022 | A1 |
20220378410 | Hacohen et al. | Dec 2022 | A1 |
20220387174 | Schwarcz et al. | Dec 2022 | A1 |
20220409369 | Christianson et al. | Dec 2022 | A1 |
20230157816 | Perrin | May 2023 | A1 |
20230172710 | Nir | Jun 2023 | A1 |
20230190463 | Nir | Jun 2023 | A1 |
20230200990 | Chen et al. | Jun 2023 | A1 |
20230263630 | Saar et al. | Aug 2023 | A1 |
20230338140 | Cartledge et al. | Oct 2023 | A1 |
20240074855 | Atias et al. | Mar 2024 | A1 |
20240138983 | Ekvall et al. | May 2024 | A1 |
20240148496 | Christianson | May 2024 | A1 |
20240148497 | Bukin et al. | May 2024 | A1 |
Number | Date | Country |
---|---|---|
2010508093 | Mar 2010 | JP |
2013517011 | May 2013 | JP |
2014528761 | Oct 2014 | JP |
2016508858 | Mar 2016 | JP |
2016533787 | Nov 2016 | JP |
2018515306 | Jun 2018 | JP |
WO-2008055301 | May 2008 | WO |
WO-2010079427 | Jul 2010 | WO |
WO-2012035279 | Mar 2012 | WO |
WO-2017123802 | Jul 2017 | WO |
WO-2018136726 | Jul 2018 | WO |
WO-2019195860 | Oct 2019 | WO |
WO-2020061124 | Mar 2020 | WO |
WO-2020061331 | Mar 2020 | WO |
WO-2020131978 | Jun 2020 | WO |
WO-2020154735 | Jul 2020 | WO |
WO-2020181154 | Sep 2020 | WO |
WO-2020186251 | Sep 2020 | WO |
WO-2020227249 | Nov 2020 | WO |
WO-2021035032 | Feb 2021 | WO |
WO-2021040996 | Mar 2021 | WO |
WO-2021146515 | Jul 2021 | WO |
WO-2022010974 | Jan 2022 | WO |
WO-2023164489 | Aug 2023 | WO |
WO-2024081883 | Apr 2024 | WO |
Entry |
---|
Extended European Search Report for European Application No. EP20854535 dated Jun. 23, 2023, 8 pages. |
Office Action for U.S. Appl. No. 17/666,086 dated Jul. 5, 2023, 16 pages. |
Office Action for European Application No. 19863898.3 dated Mar. 24, 2023, 6 pages. |
Invitation to Pay Additional Fees for International Application No. PCT/US2023/63044, mailed Jul. 31, 2023, 2 pages. |
Extended European Search Report for European Application No. EP20856704 dated Aug. 22, 2023, 11 pages. |
International Search Report and Written Opinion for PCT Application No. PCT/US2023/063044 dated Oct. 24, 2023, 13 pages. |
Office Action European Application No. 19863898.3 dated Nov. 27, 2023, 4 pages. |
Office Action for European Application No. 20769769.9 dated Sep. 8, 2023, 4 pages. |
Office Action for Japanese Application No. JP20210516666 dated Aug. 31, 2023, 19 pages. |
Office Action for Japanese Application No. JP20210535023 dated Oct. 27, 2023, 17 pages. |
Office Action for U.S. Appl. No. 17/207,076 dated Aug. 17, 2023, 6 pages. |
Extended European Search Report for European Application No. 19863898.3, dated Apr. 29, 2022, 13 pages. |
Extended European Search Report for European Application No. 19897707.6, dated Sep. 6, 2022, 7 pages. |
Extended European Search Report for European Application No. 20745513.0, dated Sep. 20, 2022, 9 pages. |
Extended European Search Report for European Application No. 20767325.2, dated Oct. 25, 2022, 5 pages. |
Extended European Search Report for European Application No. 20769769.9, dated Oct. 17, 2022, 6 pages. |
Extended European Search Report for European Application No. 20801681.6, dated Jan. 18, 2023, 13 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/028822, dated Oct. 24, 2019, 14 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/051615, dated Mar. 2, 2020, 14 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/051957, dated Apr. 30, 2020, 16 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2019/067010, dated Mar. 10, 2020, 17 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/013240, dated Jun. 3, 2020, 7 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/015231, dated Apr. 23, 2020, 10 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/021300, dated Oct. 7, 2020, 6 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/022828, dated May 19, 2020, 12 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/031390, dated Aug. 3, 2020, 10 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/045195, dated Jan. 8, 2021, 18 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2020/047162, dated Dec. 30, 2020, 9 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2021/013570, dated Apr. 1, 2021, 9 pages. |
Office Action for U.S. Appl. No. 16/155,890, dated Feb. 8, 2019, 13 pages. |
Office Action for U.S. Appl. No. 16/163,577, dated Mar. 8, 2021, 10 pages. |
Office Action for U.S. Appl. No. 16/435,687, dated Aug. 7, 2019, 19 pages. |
Office Action for U.S. Appl. No. 16/442,504, dated Jan. 14, 2020, 11 pages. |
Office Action for U.S. Appl. No. 16/443,862, dated Nov. 12, 2021, 9 pages. |
Office Action for U.S. Appl. No. 16/445,210, dated Jan. 28, 2021, 7 pages. |
Office Action for U.S. Appl. No. 16/448,108, dated Jan. 21, 2020, 14 pages. |
Office Action for U.S. Appl. No. 16/448,108, dated Mar. 8, 2021, 8 pages. |
Office Action for U.S. Appl. No. 16/448,108, dated Sep. 1, 2020, 14 pages. |
Office Action for U.S. Appl. No. 16/449,420, dated Sep. 1, 2021, 16 pages. |
Office Action for U.S. Appl. No. 16/455,417, dated Sep. 23, 2019, 11 pages. |
Office Action for U.S. Appl. No. 16/455,740, dated Jul. 24, 2020, 7 pages. |
Office Action for U.S. Appl. No. 16/711,415, dated Jan. 18, 2022, 7 pages. |
Office Action for U.S. Appl. No. 17/062,080, dated Dec. 15, 2022, 14 pages. |
Office Action for U.S. Appl. No. 17/154,227, dated Jun. 18, 2021, 8 pages. |
Office Action for U.S. Appl. No. 17/154,227, dated Mar. 29, 2021, 6 pages. |
Office Action for U.S. Appl. No. 17/154,438, dated May 3, 2021, 16 pages. |
Office Action for U.S. Appl. No. 17/167,983, dated Apr. 13, 2021, 20 pages. |
Office Action for U.S. Appl. No. 17/167,988, dated Sep. 22, 2021, 19 pages. |
Office Action for U.S. Appl. No. 17/193,936, dated May 27, 2021, 6 pages. |
Office Action for U.S. Appl. No. 17/221,547, dated Aug. 4, 2021, 11 pages. |
Office Action for U.S. Appl. No. 17/221,547, dated Oct. 21, 2021, 9 pages. |
Office Action for U.S. Appl. No. 17/222,182, dated Sep. 2, 2021, 23 pages. |
Office Action for U.S. Appl. No. 17/222,430, dated Oct. 7, 2021, 17 pages. |
Office Action for U.S. Appl. No. 17/236,219, dated Aug. 4, 2021, 17 pages. |
Office Action for U.S. Appl. No. 17/388,983, dated Jan. 6, 2022, 11 pages. |
International Search Report and Written Opinion for International Application No. PCT/US2023/076845dated Mar. 4, 2024, 10 pages. |
Office Action and Search report for Chinese Application No. CN201980075586.9 dated Feb. 5, 2024, 15 pages. |
Office Action for Canadian Application No. CA3152042 dated Feb. 20, 2024, 5 pages. |
Office Action for Canadian Patent Application No. CA20203152632 dated Feb. 19, 2024, 4 pages. |
Office Action for European Application No. EP20200801681 dated Dec. 11, 2023, 7 pages. |
Office Action for Japanese Application No. JP20210563105 mailed Feb. 26, 2024, 8 pages. |
Office Action for Japanese Patent Application No. JP20210555207 dated Jan. 31, 2024, 6 pages. |
Office Action for Japanese Patent Application No. JP2021547343 dated Jan. 31, 2024, 6 pages. |
Office Action for Canadian Patent Application No. CA3113429 dated Feb. 13, 2024, 4 pages. |
Office Action for U.S. Appl. No. 17/526,691 dated Mar. 11, 2024, 9 pages. |
Office Action and Search report for Chinese Patent Application No. CN201980090378.6 dated Mar. 12, 2024, 28 pages. |
Office Action for Australian Application No. 2019342130 mailed May 22, 2024, 3 pages. |
Office Action for Chinese Application No. 202080074543.1, with Search Report, mailed Mar. 28, 2024, 18 pages, English translation included. |
Office Action for Japanese Application No. 2021-516666 mailed Apr. 22, 2024, 6 pages, English translation included. |
Office Action for Japanese Application No. 2021-535023 mailed Apr. 22, 2024, 4 pages, English translation included. |
Office Action for Japanese Application No. 2021-547343 mailed May 13, 2024, 4 pages, English translation included. |
Office Action for Japanese Application No. 2022-511360 mailed Apr. 18, 2024, 6 pages, English translation included. |
Office Action for Japanese Application No. 2022-513172 mailed Apr. 18, 2024, 12 pages, English translation included. |
Office Action for U.S. Appl. No. 17/707,493 mailed Mar. 29, 2024, 21 pages. |
Office Action for U.S. Appl. No. 18/410,230, mailed Jun. 4, 2024, 11 pages. |
Number | Date | Country | |
---|---|---|---|
20220395370 A1 | Dec 2022 | US |
Number | Date | Country | |
---|---|---|---|
62797201 | Jan 2019 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 17222182 | Apr 2021 | US |
Child | 17688489 | US | |
Parent | PCT/US2020/015231 | Jan 2020 | WO |
Child | 17222182 | US | |
Parent | 16455740 | Jun 2019 | US |
Child | 17222182 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16455740 | Jun 2019 | US |
Child | PCT/US2020/015231 | WO |